Vladimir Avkshtol

Vladimir Avkshtol

Auto-generated profile, based on publicly available information

Vladimir Avkshtol

Department of Radiation Oncology, University of Texas Southwestern Medical Center , Dallas, TX

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DSDavid J. Sher
David J. Sher
DMDominic Moon
Dominic Moon
DVDat Vo
Dat Vo
JWJing Wang
Jing Wang
LCLiyuan Chen
Liyuan Chen
VAVladimir Avkshtol
Vladimir Avkshtol
Purpose: Elective neck irradiation (ENI) has long been considered mandatory when treating head and neck squamous cell carcinoma (HNSCC) with definitive radiotherapy, but it is associated with significant dose to normal organs-at-risk (OAR). In this prospective phase II study, we investigated the efficacy and tolerability of eliminating ENI and strictly treating involved and suspicious lymph nodes (LN) with intensity-modulated radiotherapy. Patients and Methods: Patients with newly diagnosed HNSCC of the oropharynx, larynx, and hypopharynx were eligible for enrollment. Each LN was characterized as involved or suspicious based on radiologic criteria and an in-house artificial intelligence (AI)–based classification model. Gross disease received 70 Gray (Gy) in 35 fractions and suspicious LNs were treated with 66.5 Gy, without ENI. The primary endpoint was solitary elective volume recurrence, with secondary endpoints including patterns-of-failure and patient-reported outcomes. Results: Sixty-seven patients were enrolled, with 18 larynx/hypopharynx and 49 oropharynx cancer. With a median follow-up of 33.4 months, the 2-year risk of solitary elective nodal recurrence was 0%. Gastrostomy tubes were placed in 14 (21%), with median removal after 2.9 months for disease-free patients; no disease-free patient is chronically dependent. Grade I/II dermatitis was seen in 90%/10%. There was no significant decline in composite MD Anderson Dysphagia Index scores after treatment, with means of 89.1 and 92.6 at 12 and 24 months, respectively. Conclusions: These results suggest that eliminating ENI is oncologically sound for HNSCC, with highly favorable quality-of-life outcomes. Additional prospective studies are needed to support this promising paradigm before implementation in any nontrial setting.

26 April 2023 in Advances in Radiation Oncology
Verified
Journal Article
Open access
VAVladimir Avkshtol
Vladimir Avkshtol
BMBoyu Meng
Boyu Meng
CSChenyang Shen
Chenyang Shen
BCByong Su Choi
Byong Su Choi
COChikasirimobi Okoroafor
Chikasirimobi Okoroafor
MLMu-Han Lin
Mu-Han Lin
The advent of cone beam computed tomography–based online adaptive radiation therapy (oART) has dramatically reduced the barriers of adaptation. We present the first prospective oART experience data in radiation of head and neck cancers (HNC). Patients with HNC receiving definitive standard fractionation (chemo)radiation who underwent at least 1 oART session were enrolled in a prospective registry study. The frequency of adaptations was at the discretion of the treating physician. Physicians were given the option of delivering 1 of 2 plans during adaptation: the original radiation plan transposed onto the cone beam computed tomography with adapted contours (scheduled), and a new adapted plan generated from the updated contours (adapted). A paired t test was used to compare the mean doses between scheduled and adapted plans. Twenty-one patients (15 oropharynx, 4 larynx/hypopharynx, 2 other) underwent 43 adaptation sessions (median, 2). The median ART process time was 23 minutes, median physician time at the console was 27 minutes, and median patient time in the vault was 43.5 minutes. The adapted plan was chosen 93% of the time. The mean volume in each planned target volume (PTV) receiving 100% of the prescription dose for the scheduled versus adapted plan for high-risk PTVs was 87.8% versus 95% (P < .01), intermediate-risk PTVs was 87.3% versus 97.9% (P < .01), and low-risk PTVs was 94% versus 97.8% (P < .01), respectively. The mean hotspot was also lower with adaptation: 108.8% versus 106.4% (P < .01). All but 1 organ at risk (11/12) saw a decrease in their dose with the adapted plans, with the mean ipsilateral parotid (P = .013), mean larynx (P < .01), maximum point spinal cord (P < .01), and maximum point brain stem (P = .035) reaching statistical significance. Online ART is feasible for HNC, with significant improvement in target coverage and homogeneity and a modest decrease in doses to several organs at risk.

20 August 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
DSDavid J Sher
David J Sher
VAVladimir Avkshtol
Vladimir Avkshtol
MLMu-Han Lin
Mu-Han Lin
JWJing Wang
Jing Wang
LCLiyuan Chen
Liyuan Chen
DMDominic Moon
Dominic Moon
Background: The utility of adaptive radiotherapy (ART) for head and neck squamous cell carcinoma (HNSCC) remains poorly defined. Daily ART (DART) promises both anatomic adaptation and planning target volume (PTV) reduction. In this prospective trial using cone-beam computed tomography-based ART, patients with HNSCC undergoing definitive radiotherapy (RT) or chemoradiotherapy (CRT) were randomly assigned to DART with reduced PTV margins or no ART with standard margins (image-guided RT [IGRT]). Methods: Eligibility criteria included a diagnosis of oropharynx, larynx, or hypopharynx HNSCC receiving definitive radiotherapy. All individuals received involved nodal radiotherapy per previous institutional study. The PTV margins were 1 mm (2 mm craniocaudal) vs 5 mm in the DART and IGRT arms, respectively. The primary endpoint was patient-reported xerostomia at 1 year, assessed with the Xerostomia Questionnaire (XQ). Results: Fifty patients were enrolled (26 IGRT, 24 DART) between March 2022 and June 2023. The cohort consisted of 38 oropharynx and 12 larynx/hypopharynx patients. The mean ipsilateral parotid gland, ipsilateral and contralateral submandibular gland doses were significantly lower with DART. There was significantly less acute dermatitis in the DART arm (Grade 0/1/2 0%/69%/31% vs 17%/75%/8% DART, P = .01) but no significant difference in any patient-reported outcome at 1 year. The adjusted difference in XQ score at 1 year was 10.0 (95% CI = −4.7 to 24.7, P = .58). Conclusion: Online DART for HNSCC is oncologically sound and improved acute toxicity profiles, but it did not reduce patient-reported xerostomia, the primary endpoint. Additional evidence is needed to understand the potential benefits and limitations of this paradigm, including its cost-effectiveness. Trial registration: clinicaltrials.gov identifier, NCT04883281

9 February 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
VAVladimir Avkshtol
Vladimir Avkshtol
EHElizabeth A. Handorf
Elizabeth A. Handorf
JRJohn A. Ridge
John A. Ridge
BLBrooke K. Leachman
Brooke K. Leachman
JLJeffrey C. Liu
Jeffrey C. Liu
TGThomas J. Galloway
Thomas J. Galloway

20 May 2025 in Clinical Oncology
Verified
Journal Article
Closed access
TMT.A. Mickel
T.A. Mickel
DMD.H. Moon
D.H. Moon
VAV. Avkshtol
V. Avkshtol
NPN.-L. Pham
N.-L. Pham
JSJ.L. Shah
J.L. Shah
DSD.J. Sher
D.J. Sher

1 December 2021 in Oral Oncology
Verified
Journal Article
Closed access
KBKevin Burningham
Kevin Burningham
WMWilliam Moore
William Moore
DMDominic Moon
Dominic Moon
VAVladimir Avkshtol
Vladimir Avkshtol
ADAndrew T. Day
Andrew T. Day
DSDavid J. Sher
David J. Sher